World's Best Scientists 2026 revealed!
Norihiro Nishimoto

Norihiro Nishimoto

D-Index & Metrics

Immunology

D-Index
75
Citations
29511
World Ranking
1953
National Ranking
77

Norihiro Nishimoto publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Norihiro Nishimoto sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 220 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Norihiro Nishimoto D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Norihiro Nishimoto sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 75 D-Index — 61st percentile

61% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Norihiro Nishimoto is a researcher affiliated with Osaka University in Japan, focusing primarily on the field of medicine. Their research spans several subfields including rheumatology, molecular biology, pathology and forensic medicine, orthopedics and sports medicine, and surgery.

Their scientific contributions cover a variety of topics, notably:

  • Lymphoma Diagnosis and Treatment
  • Spondyloarthritis Studies and Treatments
  • Bone and Joint Diseases
  • Hip Disorders and Treatments
  • Protein Purification and Stability
  • Microencapsulation and Drying Processes
  • Analytical Chemistry and Chromatography

Among their recent publications are the following papers:

  • "A nationwide questionnaire survey on the prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis in Japan", 2021, published in Modern Rheumatology
  • "Quantitative Analysis of Glassy State Relaxation and Ostwald Ripening during Annealing Using Freeze-Drying Microscopy", 2022, published in Pharmaceutics
  • "Selection of treatment regimens based on shared decision-making in patients with rheumatoid arthritis on remission in the FREE-J study", 2022, published in Lara D. Veeken
  • "WITHDRAWN: Ten-year follow-up of patients with refractory systemic juvenile idiopathic arthritis after the clinical trial of tocilizumab as a first biologic disease-modifying antirheumatic drug", 2025, published in EULAR Rheumatology Open
  • "Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor antibody, in 342 Japanese patients with multicentric Castleman disease: a 3-year, prospective, observational study", 2025, published in Modern Rheumatology

Frequent co-authors who have collaborated on multiple projects with Nishimoto include:

  • Tatsuya Atsumi
  • Keishi Fujio
  • Atsushi Kawakami
  • Masaaki Mori
  • Yoshiya Tanaka

Their work has been published across various venues, with repeated contributions to:

  • Modern Rheumatology
  • Pharmaceutics
  • Lara D. Veeken
  • EULAR Rheumatology Open

Best Publications

  • Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

    R Atreya;J Mudter;S Finotto;J Müllberg

  • Structure and function of a new STAT-induced STAT inhibitor

    Tetsuji Naka;Masashi Narazaki;Moritoshi Hirata;Tomoshige Matsumoto

  • Pathogenic Significance of Interleukin-6 (IL-6/BSF-2) in Castleman's Disease

    K Yoshizaki;T Matsuda;N Nishimoto;T Kuritani

  • Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial

    Norihiro Nishimoto;Kazuyuki Yoshizaki;Nobuyuki Miyasaka;Kazuhiko Yamamoto

  • Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

    Shumpei Yokota;Tomoyuki Imagawa;Masaaki Mori;Takako Miyamae

  • Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease

    Norihiro Nishimoto;Yuzuru Kanakura;Katsuyuki Aozasa;Takeshi Johkoh

  • Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

    Norihiro Nishimoto;Kimio Terao;Toru Mima;Hideko Nakahara

  • Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

    Norihiro Nishimoto;Jun Hashimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto

  • A pilot randomized Trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

    Hiroaki Ito;Masakazu Takazoe;Yoshihiro Fukuda;Toshifumi Hibi

  • TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling

    Christoph Becker;Massimo C. Fantini;Christoph Schramm;Hans A. Lehr

  • Interleukin 6: from bench to bedside.

    Norihiro Nishimoto;Tadamitsu Kishimoto

  • Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trial

    Ernest Choy;D A Isenberg;Toby Garrood;S Farrow

  • The paradigm of IL-6: from basic science to medicine

    Tetsuji Naka;Norihiro Nishimoto;Tadamitsu Kishimoto

  • Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

    Norihiro Nishimoto;Norihiro Nishimoto;Mitsuko Sasai;Mitsuko Sasai;Yoshihito Shima;Yoshihito Shima;Masashi Nakagawa;Masashi Nakagawa

  • The IL-6/JAK/Stat3 Feed-Forward Loop Drives Tumorigenesis and Metastasis

    Qing Chang;Eirini Bournazou;Pasquale Sansone;Marjan Berishaj

  • Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.

    Shumpei Yokota;Takako Miyamae;Tomoyuki Imagawa;Naomi Iwata

  • Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.

    Hideko Nakahara;Jian Song;Masamichi Sugimoto;Keisuke Hagihara

  • Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

    Norihiro Nishimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto;Shinichi Kawai

  • Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

    Norihiro Nishimoto;Nobuyuki Miyasaka;Kazuhiko Yamamoto;Shinichi Kawai

  • Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis

    Nobuhiro Takagi;Masahiko Mihara;Yoichiro Moriya;Norihiro Nishimoto

Frequent Co-Authors

Kazuyuki Yoshizaki
Kazuyuki Yoshizaki Osaka University
Tadamitsu Kishimoto
Tadamitsu Kishimoto Osaka University
Tsuneyo Mimori
Tsuneyo Mimori Kyoto University
Yoshiya Tanaka
Yoshiya Tanaka University of Occupational and Environmental Health Japan
Masahiro Iwamoto
Masahiro Iwamoto University of Maryland, Baltimore
Tsutomu Takeuchi
Tsutomu Takeuchi Keio University
Hideki Yoshikawa
Hideki Yoshikawa Osaka University
Takayuki Sumida
Takayuki Sumida University of Tsukuba
David T. Curiel
David T. Curiel Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various healthcare and research careers, many of which can be complemented by online degrees. For those looking to advance quickly in nursing, an accelerated fnp program offers a fast track to becoming a family nurse practitioner, combining clinical expertise with immunological knowledge.

Alternatively, individuals without a nursing background can still enter the field through the best online bsn programs for non nurses. These programs provide foundational nursing skills while allowing students to specialize in relevant areas such as infectious diseases or immunology.

Those seeking quicker entry points might consider accelerated nursing programs near me, which offer more accessible admissions and condensed coursework. Similarly, the best easiest lpn programs to get into help students start their nursing careers promptly, providing a pathway toward specialization or further education.

Overall, these varied online programs support diverse career pathways in healthcare and immunology, allowing flexibility and accelerated progress for students with different backgrounds and goals.

Best Scientists Citing Norihiro Nishimoto

Trending Scientists

Recently Published Articles